TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Abstract Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab,...

Full description

Bibliographic Details
Main Authors: Christos Vaklavas, Brian S. Roberts, Katherine E. Varley, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Shannon Puhalla, Rita Nanda, Anna Maria Storniolo, Lisa A. Carey, Mansoor N. Saleh, Yufeng Li, Jennifer F. Delossantos, William E. Grizzle, Albert F. LoBuglio, Richard M. Myers, Andres Forero-Torres, on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Breast Cancer Research
Subjects:
Preoperative therapy
Bevacizumab
Letrozole
Breast cancer
Hormone receptor-positive breast cancer
Luminal breast cancer
Online Access:http://link.springer.com/article/10.1186/s13058-020-01258-x

Internet

http://link.springer.com/article/10.1186/s13058-020-01258-x

Similar Items